The Chemours Company is a publicly traded company with stock symbol ‘CC’. It has a market capitalization of $5.2 billion and annual revenue of $17.77 bln as of October 26th 2022. The Price to Earnings ratio (PE) of The Chemours Company is 9.61 which indicates that it is potentially undervalued at the current price point.
The company’s Revenue performance has been mixed over the last 5 quarters ending 31 December 2022, with an average quarterly Revenue reported of approximately $1.7 bln and year-to-date Revenue estimated at $1.27 bln on 9 February 2023. Reports from 2 May 2022, 10 February 2022 and 28 July 2022 had total Revenues of $1.76 bln, $1.58 bln and $1.91 bln respectively indicating steady but largely stable growth for the company during this period.
Overall, The Chemours Company appears to have a relatively healthy financial situation based on its Revenue figures over the past 5 quarters, indicating that its core operations are performing well and that it has potential for further growth in future quarters should its operations continue to perform at current levels or better.
